BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29807205)

  • 1. Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine.
    Bretagne CH; Jooste V; Guenat D; Riethmuller D; Bouvier AM; Bedgedjian I; Prétet JL; Valmary-Degano S; Mougin C
    J Gynecol Obstet Hum Reprod; 2018 Dec; 47(10):525-531. PubMed ID: 29807205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
    Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
    Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
    Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
    J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-risk human papillomavirus cervical infections among healthy women in Guadeloupe.
    Cordel N; Ragin C; Trival M; Tressières B; Janky E
    Int J Infect Dis; 2015 Dec; 41():13-6. PubMed ID: 26597118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica.
    Safaeian M; Herrero R; Hildesheim A; Quint W; Freer E; Van Doorn LJ; Porras C; Silva S; González P; Bratti MC; Rodriguez AC; Castle P;
    J Clin Microbiol; 2007 May; 45(5):1447-54. PubMed ID: 17344361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK; Alkhateeb FM
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of high-risk human papillomavirus (HR-HPV) infection among women with normal and abnormal cervical cytology in Myanmar.
    Mu-Mu-Shwe ; Harano T; Okada S; Aye-Aye-Win ; Khin-Saw-Aye ; Hlaing-Myat-Thu ; Mo-Mo-Win ; Khin-Khin-Oo ; Myo-Khin
    Acta Med Okayama; 2014; 68(2):79-87. PubMed ID: 24743783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High risk human papillomavirus prevalence and genotype distribution among women infected with HIV in Manaus, Amazonas.
    Teixeira MF; Sabidó M; Leturiondo AL; de Oliveira Ferreira C; Torres KL; Benzaken AS
    Virol J; 2018 Feb; 15(1):36. PubMed ID: 29454382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study.
    Debrah O; Agyemang-Yeboah F; Donkoh ET; Asmah RH
    BMC Womens Health; 2021 Oct; 21(1):372. PubMed ID: 34702246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Status of HPV vaccination among HPV-infected women aged 20-60 years with abnormal cervical cytology in South Korea: a multicenter, retrospective study.
    Seong J; Ryou S; Yoo M; Lee J; Kim K; Jee Y; Cho CH; Kim SM; Hong SR; Jeong DH; Lee WC; Park JS; Kim TJ; Kee MK
    J Gynecol Oncol; 2020 Jan; 31(1):e4. PubMed ID: 31788994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytology and high risk HPV testing in cervical cancer screening program: Outcome of 3-year follow-up in an academic institute.
    Yang J; Nolte FS; Chajewski OS; Lindsey KG; Houser PM; Pellicier J; Wang Q; Ehsani L
    Diagn Cytopathol; 2018 Jan; 46(1):22-27. PubMed ID: 29048733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
    Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
    BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria.
    Borena W; Grünberger M; Widschwendter A; Kraxner KH; Marth E; Mayr P; Meier J; Ruth N; Guerrero AT; Marth C; Holm-von Laer D
    BMC Public Health; 2016 Aug; 16(1):889. PubMed ID: 27565569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program.
    Tabrizi SN; Brotherton JM; Stevens MP; Condon JR; McIntyre P; Smith D; Garland SM;
    J Clin Virol; 2014 Jul; 60(3):250-6. PubMed ID: 24854516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.